Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Sponsor
Qingdao Central Hospital
Study ID
NCT04974879
Phase
PHASE2
Status
Unknown

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Osimertinib Oral Tablet — DRUG
    Osimertinib, 80mg, oral daily; bevacizumab (avastin), 15mg/KG body weight, erery 21 days, intravenously.

Study Details

There is no muture method to treat EGFR 20 insertion mutation non-small-cell lung cancer (NSCLC). the he purpose of this study is to study osimertinib combined with bevacizumab in the management of it.

Key Dates

Start date
Jul 1, 2021
Status verified
Mar 2023
Primary completion
Jul 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: study drug
    osimertinib oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.

Primary Outcome Measure

Progression free survival [ Time Frame: 18 months ]

Related Studies